FBIO - Fortress Biotech Inc Stock Price, Fair Value and News

1.70USD-0.02 (-1.16%)Market Closed

Market Summary

USD1.70-0.02

Market Closed

-1.16%

FBIO Stock Price

View Fullscreen

FBIO RSI Chart

FBIO Valuation

Market Cap

25.7M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

0.3

EV/EBITDA

0.4

Price/Free Cashflow

-0.2

FBIO Price/Sales (Trailing)

FBIO Profitability

EBT Margin

-176.59%

Return on Equity

-268.97%

Return on Assets

-36.2%

Free Cashflow Yield

-499.99%

FBIO Fundamentals

FBIO Revenue

Revenue (TTM)

84.5M

Rev. Growth (Yr)

21.59%

Rev. Growth (Qtr)

-42.6%

FBIO Earnings

Earnings (TTM)

-60.6M

Earnings Growth (Yr)

65.57%

Earnings Growth (Qtr)

-83.92%

Breaking Down FBIO Revenue

Last 7 days

-2.9%

Last 30 days

-21.7%

Last 90 days

-17.5%

Trailing 12 Months

129.7%

How does FBIO drawdown profile look like?

FBIO Financial Health

Current Ratio

1.38

Debt/Equity

11.39

Debt/Cashflow

-7.09

FBIO Investor Care

Shares Dilution (1Y)

104.89%

Diluted EPS (TTM)

-8.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	64.2M	62.7M	81.0M	84.5M
2022	70.2M	73.0M	74.4M	75.7M
2021	44.3M	52.7M	64.3M	68.8M
2020	43.1M	43.3M	43.0M	45.6M
2019	27.5M	29.9M	34.5M	36.6M
2018	152.9M	67.1M	25.4M	26.9M
2017	20.4M	110.8M	156.7M	149.8M
2016	1.0M	3.3M	4.2M	18.3M
2015	0	0	0	863.0K
2014	0	0	0	0
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fortress Biotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	jin david	acquired	3,998	1.7	2,352	chief financial officer
Jan 05, 2024	rosenwald lindsay a md	bought	118,770	2.3754	50,000	president, ceo & chairman
Jan 01, 2024	harvey jimmie	acquired	-	-	6,666	-
Jan 01, 2024	klein dov	acquired	-	-	6,666	-
Jan 01, 2024	lorenz kevin	acquired	-	-	3,333	-
Jan 01, 2024	rowinsky eric k	acquired	-	-	6,666	-
Jan 01, 2024	rosenwald lindsay a md	acquired	-	-	216,465	president, ceo & chairman
Jan 01, 2024	weiss michael s	acquired	-	-	216,465	see remarks
Jan 01, 2024	hoenlein malcolm	acquired	-	-	3,333	-
Jan 01, 2024	lu lucy	acquired	-	-	3,333	-

Which funds bought or sold FBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Rosalind Advisors, Inc.	unchanged	-	-613,875	1,215,590	1.14%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-5,000	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-134	266	-%
Apr 22, 2024	SHIKIAR ASSET MANAGEMENT INC	added	21.84	-104,000	446,000	0.13%
Apr 22, 2024	PFG Investments, LLC	new	-	32,582	32,582	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-46.28	-183,524	101,872	-%
Apr 12, 2024	Wealth Management Partners, LLC	sold off	-100	-60,200	-	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-42,006	-	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	new	-	258,785	258,785	0.01%
Mar 12, 2024	PVG ASSET MANAGEMENT CORP	new	-	395,784	395,784	1.91%

Are Funds Buying or Selling FBIO?

Are funds buying FBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FBIO

No. of Funds

Unveiling Fortress Biotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	4.2%	372,562	SC 13G/A
Jan 03, 2024	rosenwald lindsay a md	15.3%	2,813,905	SC 13D/A
Nov 21, 2023	weiss michael s	7.6%	1,130,520	SC 13D/A
Nov 21, 2023	rosenwald lindsay a md	17.5%	2,597,440	SC 13D/A
Feb 14, 2023	katz daryl	4.76%	6,052,975	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	7.3%	7,968,056	SC 13G/A
Feb 09, 2023	vanguard group inc	4.70%	5,104,407	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	9.6%	9,086,005	SC 13G/A
May 07, 2021	blackrock inc.	5.0%	4,814,223	SC 13G/A
Feb 16, 2021	nantahala capital management, llc	9.3%	8,680,909	SC 13G

Recent SEC filings of Fortress Biotech Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 17, 2024	4	Insider Trading
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	424B3	Prospectus Filed
Apr 02, 2024	4	Insider Trading
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 22, 2024	SC 13D/A	13D - Major Acquisition
Mar 22, 2024	4	Insider Trading

Peers (Alternatives to Fortress Biotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Fortress Biotech Inc News

Latest updates

Fortress Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-42.6%	19,946,000	34,752,000	17,386,000	12,429,000	16,404,000	16,528,000	18,886,000	23,925,000	21,100,500	18,276,000	21,085,000	17,843,000	11,587,000	13,749,000	9,475,000	9,457,000	12,918,000	11,130,000	9,772,000	9,250,000	6,477,000
Costs and Expenses	-18.5%	39,559,000	48,510,000	67,491,000	71,296,000	71,038,000	67,262,000	69,812,000	71,195,000	-	82,148,500	71,008,000	60,700,000	41,604,000	38,052,000	32,518,000	34,853,000	34,446,000	41,511,000	32,312,000	34,540,000	39,085,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,540,000	39,085,000
S&GA Expenses	4.0%	22,611,500	21,733,000	24,439,000	25,341,000	28,199,000	30,139,000	29,048,000	26,270,000	-	27,698,000	22,221,000	19,382,000	17,542,000	15,808,000	15,383,000	14,456,000	15,519,000	14,330,000	14,339,000	13,443,000	13,478,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,273,000
EBITDA Margin	-Infinity%	-1.65	-	-3.18	-3.10	-2.65	-2.06	-2.11	-2.16	-2.21	-2.25	-1.46	-1.75	-2.08	-2.02	-2.13	-2.16	-2.18	-2.57	-2.80	-3.43	-
Interest Expenses	-7.1%	1,355,000	1,459,000	2,246,000	2,885,000	2,824,000	2,608,000	2,431,000	1,556,000	-	1,893,000	1,686,000	1,669,000	1,670,000	1,535,000	3,504,000	1,556,000	1,609,000	1,468,000	1,438,000	1,438,000	1,100,000
Income Taxes	168.8%	379,000	141,000	52,000	-104,000	449,000	-	59,000	107,000	-	-188,000	157,000	504,000	-	500,000	-	-	-	-2,388,500	-	-	-
Earnings Before Taxes	-170.3%	-28,605,000	-10,583,000	-	-	-56,996,000	-53,060,000	-	-	-	-	-	-	-	-	-	-	-	-32,955,000	-24,970,000	-27,480,000	-16,255,000
EBT Margin	-Infinity%	-1.77	-	-3.40	-3.32	-2.82	-2.21	-2.25	-2.30	-2.34	-2.39	-1.60	-1.95	-2.32	-2.26	-2.37	-2.35	-2.36	-2.78	-3.00	-3.67	-
Net Income	-83.9%	-9,279,000	-5,045,000	-24,776,000	-21,537,000	-26,948,000	-22,511,000	-21,356,000	-15,760,000	-	-31,565,000	-20,781,000	-3,535,000	-8,822,000	-5,295,000	-15,547,000	-13,314,000	-12,370,000	-15,492,000	-12,762,000	-13,098,000	1,392,000
Net Income Margin	51.2%	-0.72	-1.47	-2.18	-2.07	-1.68	-1.23	-1.23	-1.00	-0.92	-0.94	-0.60	-0.63	-0.97	-1.02	-1.32	-1.25	-1.25	-1.09	-1.43	-	-
Free Cashflow	-108.4%	-34,963,000	-16,780,000	-33,325,000	-43,220,000	-47,935,000	-44,253,000	-41,731,000	-48,197,000	-40,653,000	-40,653,000	-22,157,000	-36,150,000	-22,146,000	-21,184,000	-23,371,000	-18,635,000	-22,418,000	-25,942,000	-16,764,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	11.3%	168	151	181	264	294	324	364	408	397	408	418	391	333	296	269	229	226	222	227	201	141
Current Assets	19.6%	117	98.00	128	202	230	258	299	341	346	301	320	318	266	238	200	159	156	166	164	137	111
Cash Equivalents	11.9%	81.00	72.00	78.00	152	178	208	249	288	308	253	275	290	235	218	183	153	153	151	165	133	82.00
Inventory	-7.4%	10.00	11.00	12.00	13.00	14.00	15.00	16.00	16.00	10.00	12.00	14.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-5.1%	7.00	7.00	7.00	12.00	13.00	14.00	14.00	14.00	15.00	14.00	13.00	12.00	12.00	12.00	12.00	13.00	12.00	12.00	12.00	12.00	12.00
Liabilities	1.3%	166	164	197	244	244	222	216	214	171	195	170	147	136	120	152	153	154	147	137	150	121
Current Liabilities	-12.8%	85.00	97.00	129	129	128	106	105	103	101	103	71.00	54.00	52.00	37.00	57.00	52.00	46.00	47.00	36.00	49.00	56.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	18.00	13.00	11.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	18.00	13.00	11.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	35.2%	23.00	17.00	19.00	20.00	42.00	101	148	194	226	212	248	244	197	176	117	75.00	73.00	75.00	90.00	51.00	20.00
Retained Earnings	-1.4%	-694	-685	-680	-655	-634	-607	-584	-563	-547	-515	-495	-491	-482	-477	-461	-448	-436	-420	-407	-394	-396
Additional Paid-In Capital	2.2%	717	702	699	693	676	669	662	661	656	608	603	597	583	574	521	485	462	446	439	415	397
Shares Outstanding	68.9%	15.00	9.00	9.00	9.00	7.00	6.00	6.00	6.00	7.00	5.00	5.00	5.00	6.00	5.00	5.00	4.00	5.00	4.00	3.00	-	-
Minority Interest	29.9%	-20.96	-29.92	-34.45	-17.99	8.00	40.00	70.00	96.00	117	120	140	138	97.00	79.00	56.00	38.00	46.00	49.00	58.00	30.00	18.00
Float	-	-	-	53.00	-	-	-	66.00	-	-	-	254	-	-	-	174	-	-	-	71.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-108.2%	-34,935	-16,779	-33,291	-43,220	-47,844	-43,273	-41,424	-46,860	-38,696	-21,696	-34,460	-21,688	-20,486	-23,892	-17,412	-21,892	-25,052	-16,264	-28,320	-25,325	-22,160
Share Based Compensation	-15.4%	3,704	4,377	4,217	4,731	5,506	6,837	5,081	5,563	7,037	4,326	4,350	3,773	3,132	3,171	3,748	3,400	2,765	3,741	3,373	3,309	2,959
Cashflow From Investing	-101.3%	-63.00	4,999	-2,039	-5,000	-391	-893	-307	-21,337	53,353	-7,541	-4,840	-458	-1,567	-2,758	-1,063	-1,776	310	-3,750	-611	24,148	13,522
Cashflow From Financing	1724.5%	43,618	-2,685	-30,381	22,187	18,618	3,746	2,991	49,964	38,941	6,966	24,395	78,692	37,015	46,832	65,810	22,753	27,155	5,552	61,894	52,113	-1,692
Dividend Payments	-2.7%	180	185	185	186	186	188	188	187	187	187	188	187	187	50.00	-	-	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.00	-82.00	-	-	-	-

FBIO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Product revenue, net	$ 59,662	$ 70,995
Collaboration revenue	5,229	1,882
Other revenue	19,519	2,674
Net revenue	84,513	75,743
Operating expenses
Cost of goods sold - product revenue	26,660	30,775
Research and development	101,747	134,199
Research and development - licenses acquired	4,324	677
Selling, general and administrative	94,124	113,656
Asset impairment	3,100
Total operating expenses	226,855	279,307
Loss from operations	(142,342)	(203,564)
Other income (expense)
Interest income	3,003	1,398
Interest expense and financing fee	(15,315)	(13,642)
Change in fair value of warrant liabilities	4,424	1,129
Other income (expense)	(3,403)	1,215
Total other income (expense)	(11,291)	(9,900)
Loss before income tax expense	(153,633)	(213,464)
Income tax expense	521	449
Net loss	(154,154)	(213,913)
Net loss attributable to non-controlling interests	93,517	127,338
Net loss attributable to Fortress	(60,637)	(86,575)
Preferred A dividends declared and paid	(8,032)	(8,032)
Net loss attributable to common stockholders	$ (68,669)	$ (94,607)
Net loss per common share attributable to common stockholders - basic	$ (8.47)	$ (15.97)
Net loss per common share attributable to common stockholders - diluted	$ (8.47)	$ (15.97)
Weighted average common shares outstanding - basic	8,110,906	5,924,967
Weighted average common shares outstanding - diluted	8,110,906	5,924,967
Related Party [Member]
Revenue
Revenue - related party	$ 103	$ 192

FBIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 80,927	$ 178,266
Accounts receivable, net	15,222	28,208
Inventory	10,206	14,159
Prepaid expenses and other current assets	10,500	9,661
Total current assets	117,022	230,432
Property, plant and equipment, net	6,505	13,020
Operating lease right-of-use asset, net	16,990	19,991
Restricted cash	2,438	2,688
Intangible asset, net	20,287	27,197
Other assets	4,284	973
Total assets	167,526	294,301
Current liabilities
Accounts payable and accrued expenses	73,562	97,446
Income taxes payable	843	722
Common stock warrant liabilities	886	13,869
Operating lease liabilities, short-term	2,523	2,447
Partner company convertible preferred shares, short-term, net	3,931	2,052
Partner company line of credit	0	2,948
Partner company installment payments - licenses, short-term, net	3,000	7,235
Other short-term liabilities	163	996
Total current liabilities	84,908	127,715
Notes payable, long-term, net	60,856	91,730
Operating lease liabilities, long-term	18,282	21,572
Partner company installment payments - licenses, long-term, net	0	1,412
Other long-term liabilities	1,893	1,847
Total liabilities	165,939	244,276
Stockholders' equity (deficit)
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively, liquidation value of $25.00 per share	3	3
Common stock, $0.001 par value, 200,000,000 shares authorized, 15,073,445 and 7,366,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	15	7
Additional paid-in-capital	717,396	675,944
Accumulated deficit	(694,870)	(634,233)
Total stockholders' equity attributed to the Company	22,544	41,721
Non-controlling interests	(20,957)	8,304
Total stockholders' equity (deficit)	1,587	50,025
Total liabilities and stockholders' equity (deficit)	167,526	294,301
Related Party
Current assets
Other receivables - related party	$ 167	$ 138

About Fortress Biotech Inc

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

CEO	Dr. Lindsay Allan Rosenwald
WEBSITE	fortressbiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	187

Fortress Biotech Inc Frequently Asked Questions

What is the ticker symbol for Fortress Biotech Inc? What does FBIO stand for in stocks?

FBIO is the stock ticker symbol of Fortress Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fortress Biotech Inc (FBIO)?

As of Fri Apr 26 2024, market cap of Fortress Biotech Inc is 25.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FBIO stock?

You can check FBIO's fair value in chart for subscribers.

What is the fair value of FBIO stock?

You can check FBIO's fair value in chart for subscribers. The fair value of Fortress Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fortress Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fortress Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether FBIO is over valued or under valued. Whether Fortress Biotech Inc is cheap or expensive depends on the assumptions which impact Fortress Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FBIO.

What is Fortress Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, FBIO's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 0.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fortress Biotech Inc's stock?

In the past 10 years, Fortress Biotech Inc has provided -0.004 (multiply by 100 for percentage) rate of return.